CN Mobile Logo

Search form


ASCO Multiple Myeloma

Multiple Myeloma ASCO Highlights

Cancer Network presents exclusive coverage on multiple myeloma from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports, videos, and interviews on the latest clinical research changing the way myeloma patients are being managed and treated.

ASCO Multiple Myeloma

In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.

In this interview we discuss how relapse in multiple myeloma manifests and treatment options for relapsed/refractory patients.

Cardiovascular adverse events are more than twice as frequent in carfilzomib arms of randomized controlled trials in multiple myeloma, according to a systematic review and meta-analysis of 24 studies.

The combination of the anti-CD38 monoclonal antibody isatuximab with pomalidomide/dexamethasone had an acceptable and manageable safety profile in patients with relapsed or refractory multiple myeloma.

This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.

Among high-risk multiple myeloma patients, post-ASCT immunization with the Wilms tumor 1 peptide mixture galinpepimut-S is well tolerated and is associated with promising progression-free survival.

Adding daratumumab to standard of care is a feasible alternative to autologous stem cell transplantation with standard regimens in multiple myeloma patients.


Subscribe to ASCO Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.